APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01960348
Recruitment Status : Completed
First Posted : October 10, 2013
Last Update Posted : January 29, 2018
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis

Condition or disease Intervention/treatment Phase
TTR-mediated Amyloidosis Amyloidosis, Hereditary Amyloid Neuropathies, Familial Familial Amyloid Polyneuropathies Amyloid Neuropathies Amyloidosis, Hereditary, Transthyretin-Related Drug: patisiran (ALN-TTR02) Drug: Sterile Normal Saline (0.9% NaCl) Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Study Start Date : November 2013
Actual Primary Completion Date : August 2017
Actual Study Completion Date : August 2017

Arm Intervention/treatment
Active Comparator: patisiran (ALN-TTR02) Drug: patisiran (ALN-TTR02)
administered by intravenous (IV) infusion

Placebo Comparator: Sterile Normal Saline (0.9% NaCl) Drug: Sterile Normal Saline (0.9% NaCl)
administered by intravenous (IV) infusion

Primary Outcome Measures :
  1. The difference between the ALN TTR02 and placebo groups in the change from baseline of modified Neuropathy Impairment Score+7 (mNIS+7) [ Time Frame: 18 months ]

Secondary Outcome Measures :
  1. The difference between ALN-TTR02 and placebo in the change from baseline in quality of life [ Time Frame: 18 months ]
  2. The difference between ALN-TTR02 and placebo in the change from baseline in motor function [ Time Frame: 18 months ]
  3. The difference between ALN-TTR02 and placebo in the change from baseline in autonomic function [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female of 18 to 85 years of age (inclusive);
  • Have a diagnosis of FAP
  • Neuropathy Impairment Score requirement of 5-130
  • Meet Karnofsky performance status requirements
  • Have adequate complete blood counts and liver function tests
  • Have adequate cardiac function
  • Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)

Exclusion Criteria:

  • Had a prior liver transplant or is planned to undergo liver transplant during the study period;
  • Has untreated hypo- or hyperthyroidism;
  • Has known human immunodeficiency virus (HIV) infection;
  • Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;
  • Recently received an investigational agent or device
  • Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01960348

  Hide Study Locations
United States, California
Clinical Trial Site
La Mesa, California, United States
Clinical Trial Site
Orange, California, United States
United States, Colorado
Clinical Trial Site
Denver, Colorado, United States
United States, Illinois
Clinical Trial Site
Chicago, Illinois, United States
United States, Maryland
Clinical Trial Site
Baltimore, Maryland, United States
United States, Massachusetts
Clinical Trial Site
Boston, Massachusetts, United States
United States, Michigan
Clinical Trial Site
Detroit, Michigan, United States
United States, Minnesota
Clinical Trial Site
Rochester, Minnesota, United States
United States, Missouri
Clinical Trial Site
Saint Louis, Missouri, United States
United States, New York
Clinical Trial Site
New York, New York, United States, 10029
Clinical Trial Site
New York, New York, United States, 10032
United States, North Carolina
Clinical Trial Site
Durham, North Carolina, United States
United States, Oregon
Clinical Trial Site
Portland, Oregon, United States
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Westmead, Australia
Clinical Trial Site
Ribeirao Preto, Brazil
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
Sao Paulo, Brazil
Clinical Trial Site
Sofia, Bulgaria
Canada, British Columbia
Clinical Trial Site
Vancouver, British Columbia, Canada
Clinical Trial Site
Nicosia, Cyprus
Clinical Trial Site
Bourdeaux, France
Clinical Trial Site
Creteil, France
Clinical Trial Site
Le Kremlin-bicetre, France
Clinical Trial Site
Lille Cedex, France
Clinical Trial Site
Marseille Cedex, France
Clinical Trial Site
Heidelberg, Germany
Clinical Trial Site
Muenster, Germany
Clinical Trial Site
Regensburg, Germany
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Rome, Italy
Clinical Trial Site
Sicily, Italy
Clinical Trial Site
Matsumoto, Nagano, Japan
Clinical Trial Site
Aichi, Japan
Clinical Trial Site
Kumamoto, Japan
Korea, Republic of
Clinical Trial Site
Seoul, Korea, Republic of, 135-710
Clinical Trial Site
Seoul, Korea, Republic of, 143-729
Clinical Trial Site
Kuala Lumpur, Malaysia
Clinical Trial Site
Mexico City, Mexico
Clinical Trial Site
Groningen, Netherlands
Clinical Trial Site
Lisbon, Portugal
Clinical Trial Site
Porto, Portugal
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Huelva, Spain
Clinical Trial Site
Madrid, Spain
Clinical Trial Site
Palma De Mallorca, Spain
Clinical Trial Site
Umeå, Sweden
Clinical Trial Site
Taipai, Taiwan, 11217
Clinical Trial Site
Taipei, Taiwan, 10002
Clinical Trial Site
Istanbul, Turkey
United Kingdom
Clinical Trial Site
London, United Kingdom, NW32PF
Clinical Trial Site
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
Alnylam Pharmaceuticals
Study Director: Jared Gollob Alnylam Pharmaceuticals

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Alnylam Pharmaceuticals Identifier: NCT01960348     History of Changes
Other Study ID Numbers: ALN-TTR02-004
2013-002987-17 ( EudraCT Number )
First Posted: October 10, 2013    Key Record Dates
Last Update Posted: January 29, 2018
Last Verified: January 2018

Keywords provided by Alnylam Pharmaceuticals:
RNAi therapeutic
Familial Amyloid Polyneuropathy

Additional relevant MeSH terms:
Amyloid Neuropathies
Amyloid Neuropathies, Familial
Amyloidosis, Familial
Proteostasis Deficiencies
Metabolic Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Metabolism, Inborn Errors